Xospata

RSS

gilteritinib

Authorised
This medicine is authorised for use in the European Union.

Overview

Xospata is a cancer medicine used to treat adults with acute myeloid leukaemia (AML), a cancer of white blood cells.

Xospata is used when AML has either come back or has not improved following previous treatment and is only given to patients whose cancer cells have a particular change (mutation) in the gene for a protein called FLT3.

The active substance in Xospata is gilteritinib.

AML is rare, and Xospata was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 January 2018.

This EPAR was last updated on 08/11/2019

Authorisation details

Product details
Name
Xospata
Agency product number
EMEA/H/C/004752
Active substance
gilteritinib fumarate
International non-proprietary name (INN) or common name
gilteritinib
Therapeutic area (MeSH)
Leukemia, Myeloid, Acute
Anatomical therapeutic chemical (ATC) code
L01XE54
OrphanOrphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Astellas Pharma Europe B.V.
Date of issue of marketing authorisation valid throughout the European Union
24/10/2019
Contact address

Sylviusweg 62
2333 BE Leiden
The Netherlands

Product information

24/10/2019 Xospata - EMEA/H/C/004752 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.

Assessment history

How useful was this page?

Add your rating